Insider Trading › NVCR › Insiders
NovoCure Ltd
NVCR·Nasdaq·Insider activity
$14.66
-0.31 (-2.07%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
NVCR
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NVCRS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
In the last 180 days, NVCR insiders filed 0 purchases ($0) and 7 sales ($893K) on the open market, by 7 insiders. Newest filing Jun 5, 2026 (4 months ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by NVCR insiders · Form 4 · last two years
On Record
$0Purchases · 180 days
$893KSales · 180 days
923Open-market transactions on record
7Insiders filing · 180 days
Purchases (code P) and sales (code S) of NVCR common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
923 on record · newest trade first · the newest 300 shown
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Leonard Frank XChief Executive Officer | Sale | −34.3K | $17.93 | $615K | 459.5Kdirect | Jun 4, 2026 | Jun 5, 2026 | Form 4 ↗ |
| Stafford KristinDirector | Sale | −2,945 | $15.77 | $46K | 11.3Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| Ocean Allyson JDirector | Sale | −2,945 | $15.77 | $46K | 11.3Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| Scannell Timothy JDirector | Sale | −2,945 | $15.77 | $46K | 14.3Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Sale | −2,945 | $15.77 | $46K | 197.7Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| Hung DavidDirector | Sale | −2,945 | $15.77 | $46K | 20.5Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −2,945 | $15.77 | $46K | 89.5Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| HILLEMAN JERYL LDirector | Sale | −2,945 | $15.77 | $46K | 13.9Kdirect | Jun 2, 2026 | Jun 3, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −43.2K | $13.77 | $595K | 72.8Kdirect | Mar 5, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Brackmann ChristophChief Financial Officer | Sale | −6,412 | $13.31 | $85K | 182.8Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −5,377 | $13.31 | $72K | 116.1Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Leupin NicolasFormer Chief Medical Officer | Sale | −1,100 | $13.31 | $15K | 103.0Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale | −1,100 | $13.31 | $15K | 201.3Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Leonard Frank XChief Executive Officer | Sale | −5,607 | $13.31 | $75K | 493.8Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Weinberg UriChf Medical and Innovation Ofr | Sale | −6,412 | $13.31 | $85K | 267.2Kdirect | Mar 4, 2026 | Mar 5, 2026 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −21.3K | $13.43 | $286K | 328.4Kdirect | Mar 3, 2026 | Mar 5, 2026 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −50.6K | $12.79 | $647K | 349.7Kdirect | Mar 3, 2026 | Mar 5, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −408 | $13.49 | $6K | 76.3Kdirect | Mar 2, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Leonard Frank XChief Executive Officer | Sale | −7,232 | $13.49 | $98K | 349.4Kdirect | Mar 2, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Weinberg UriChf Medical and Innovation Ofr | Sale | −3,272 | $13.33 | $44K | 223.5Kdirect | Mar 2, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −1,555 | $13.66 | $21K | 76.8Kdirect | Feb 27, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Leupin NicolasFormer Chief Medical Officer | Sale | −1,029 | $13.66 | $14K | 104.1Kdirect | Feb 27, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale | −1,441 | $13.66 | $20K | 162.3Kdirect | Feb 27, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Leonard Frank XChief Executive Officer | Sale | −9,734 | $13.66 | $133K | 338.0Kdirect | Feb 27, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Weinberg UriChf Medical and Innovation Ofr | Sale | −7,461 | $13.84 | $103K | 213.8Kdirect | Feb 27, 2026 | Mar 3, 2026 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Purchase | +81.5K | $12.22 | $997K | 437.6Kdirect | Sep 5, 2025 | Sep 8, 2025 | Form 4 ↗ |
| Brackmann ChristophChief Financial Officer | Purchase | +5,000 | $11.50 | $58K | 141.2Kdirect | Jul 29, 2025 | Jul 30, 2025 | Form 4 ↗ |
| Brackmann ChristophChief Financial Officer | Purchase | +5,000 | $11.60 | $58K | 136.2Kdirect | Jul 29, 2025 | Jul 30, 2025 | Form 4 ↗ |
| Brackmann ChristophChief Financial Officer | Purchase | +10.0K | $11.63 | $116K | 131.2Kdirect | Jul 29, 2025 | Jul 30, 2025 | Form 4 ↗ |
| Stafford KristinDirector | Sale | −999 | $17.28 | $17K | 3,054direct | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −999 | $17.31 | $17K | 81.2Kdirect | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Madden Martin J.Director | Sale | −999 | $17.19 | $17K | 18.7Kdirect | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Scannell Timothy JDirector | Sale | −999 | $17.32 | $17K | 6,018direct | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| HILLEMAN JERYL LDirector | Sale | −999 | $17.26 | $17K | 5,591direct | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Ocean Allyson JDirector | Sale | −999 | $17.29 | $17K | 3,054direct | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Sale | −999 | $17.35 | $17K | 167.9Kdirect | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Hung DavidDirector | Sale | −999 | $17.30 | $17K | 12.2Kdirect | Jun 3, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −1,879 | $19.01 | $36K | 168.5Kdirect | Jun 2, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −6,600 | $17.99 | $119K | 170.3Kdirect | Jun 2, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −21.7K | $17.22 | $374K | 176.9Kdirect | Jun 2, 2025 | Jun 4, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −592 | $17.91 | $11K | 83.6Kdirect | May 3, 2025 | May 5, 2025 | Form 4 ↗ |
| Weinberg UriChief Innovation Officer | Sale | −268 | $18.92 | $5K | 166.2Kdirect | Mar 3, 2025 | Mar 4, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −2,527 | $18.54 | $47K | 143.7Kdirect | Mar 3, 2025 | Mar 4, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale | −2,053 | $18.54 | $38K | 204.0Kdirect | Mar 3, 2025 | Mar 4, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −250 | $18.54 | $5K | 29.2Kdirect | Mar 3, 2025 | Mar 4, 2025 | Form 4 ↗ |
| Weinberg UriChief Innovation Officer | Sale Amended | −311 | $18.31 | $6K | 166.5Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Weinberg UriChief Innovation Officer | Sale Amended | −4,326 | $18.78 | $81K | 166.8Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale Amended | −2,341 | $18.28 | $43K | 206.1Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale Amended | −2,770 | $18.28 | $51K | 146.2Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale Amended | −368 | $18.28 | $7K | 29.4Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Weinberg UriChief Innovation Officer | Sale | −311 | $18.31 | $6K | 166.5Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Weinberg UriChief Innovation Officer | Sale | −4,326 | $18.78 | $81K | 166.8Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −2,770 | $18.28 | $51K | 146.2Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale | −2,341 | $18.28 | $43K | 206.1Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −368 | $18.28 | $7K | 29.4Kdirect | Feb 28, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale Amended | −1,808 | $20.55 | $37K | 208.4Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale Amended | −9,345 | $19.92 | $186K | 210.2Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale Amended | −1,989 | $20.55 | $41K | 149.0Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale Amended | −10.3K | $19.92 | $205K | 151.0Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale Amended | −225 | $20.55 | $5K | 108.7Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale Amended | −1,162 | $19.92 | $23K | 108.9Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leupin NicolasChief Medical Officer | Sale Amended | −161 | $20.55 | $3K | 50.1Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leupin NicolasChief Medical Officer | Sale Amended | −830 | $19.92 | $17K | 50.3Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale Amended | −267 | $20.55 | $5K | 29.8Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale Amended | −1,379 | $19.92 | $27K | 30.1Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leupin NicolasChief Medical Officer | Sale | −161 | $20.55 | $3K | 50.1Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leupin NicolasChief Medical Officer | Sale | −830 | $19.92 | $17K | 50.3Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale | −225 | $20.55 | $5K | 108.7Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale | −1,162 | $19.92 | $23K | 108.9Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −1,989 | $20.55 | $41K | 149.0Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −10.3K | $19.92 | $205K | 151.0Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale | −1,808 | $20.55 | $37K | 208.4Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Cordova AshleyChief Executive Officer | Sale | −9,345 | $19.92 | $186K | 210.2Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −267 | $20.55 | $5K | 29.8Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −1,379 | $19.92 | $27K | 30.1Kdirect | Feb 27, 2025 | Mar 3, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −2,160 | $26.81 | $58K | 31.4Kdirect | Jan 11, 2025 | Jan 15, 2025 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −44 | $16.69 | $734 | 3,459direct | Nov 2, 2024 | Nov 6, 2024 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −598 | $15.94 | $10K | 161.2Kdirect | Nov 1, 2024 | Nov 4, 2024 | Form 4 ↗ |
| Paravasthu MukundChief Operating Officer | Sale | −160 | $15.88 | $3K | 3,503direct | Nov 1, 2024 | Nov 4, 2024 | Form 4 ↗ |
| Puri Michal NathChief Human Resources Officer | Sale | −810 | $15.79 | $13K | 110.1Kdirect | Oct 31, 2024 | Nov 4, 2024 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −688 | $20.14 | $14K | 219.2Kdirect | Aug 2, 2024 | Aug 5, 2024 | Form 4 ↗ |
| VERNON W ANTHONYDirector | Sale | −964 | $23.89 | $23K | 164.8Kdirect | Jun 4, 2024 | Jun 6, 2024 | Form 4 ↗ |
| Scannell Timothy JDirector | Sale | −964 | $23.89 | $23K | 2,964direct | Jun 4, 2024 | Jun 6, 2024 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −964 | $23.89 | $23K | 78.2Kdirect | Jun 4, 2024 | Jun 6, 2024 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −1,217 | $16.01 | $19K | 251.2Kdirect | Mar 4, 2024 | Mar 5, 2024 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −840 | $16.01 | $13K | 160.1Kdirect | Mar 4, 2024 | Mar 5, 2024 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,107 | $16.03 | $34K | 252.5Kdirect | Mar 1, 2024 | Mar 5, 2024 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −1,679 | $16.03 | $27K | 160.9Kdirect | Mar 1, 2024 | Mar 5, 2024 | Form 4 ↗ |
| Leonard Frank XEVP, Pres., Novocure Oncology | Sale | −2,078 | $16.14 | $34K | 162.6Kdirect | Feb 28, 2024 | Feb 29, 2024 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,303 | $16.14 | $37K | 254.6Kdirect | Feb 28, 2024 | Feb 29, 2024 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −382 | $12.65 | $5K | 124.5Kdirect | Nov 7, 2023 | Nov 8, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −883 | $21.82 | $19K | 99.7Kdirect | Sep 1, 2023 | Sep 5, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −294 | $21.82 | $6K | 209.8Kdirect | Sep 1, 2023 | Sep 5, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −273 | $21.82 | $6K | 124.9Kdirect | Sep 1, 2023 | Sep 5, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −1,144 | $30.25 | $35K | 100.5Kdirect | Aug 2, 2023 | Aug 4, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −2,315 | $75.59 | $175K | 54.3Kdirect | Mar 7, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −6,003 | $75.00 | $450K | 56.6Kdirect | Mar 7, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −888 | $76.16 | $68K | 62.6Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −4,403 | $76.16 | $335K | 63.5Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −16.9K | $76.16 | $1.3M | 124.8Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −2,942 | $76.16 | $224K | 141.7Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −1,570 | $76.16 | $120K | 144.7Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −20.4K | $76.16 | $1.6M | 209.8Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −1,692 | $76.16 | $129K | 230.2Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −3,528 | $76.16 | $269K | 231.9Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −775 | $76.16 | $59K | 101.3Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −4,730 | $76.16 | $360K | 102.1Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −593 | $76.16 | $45K | 66.1Kdirect | Mar 3, 2023 | Mar 7, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −2,059 | $77.64 | $160K | 67.9Kdirect | Mar 3, 2023 | Mar 6, 2023 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −281 | $75.28 | $21K | 66.7Kdirect | Mar 2, 2023 | Mar 6, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −937 | $75.28 | $71K | 99.0Kdirect | Mar 2, 2023 | Mar 6, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −1,213 | $75.28 | $91K | 183.4Kdirect | Mar 2, 2023 | Mar 6, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −1,055 | $75.28 | $79K | 95.0Kdirect | Mar 2, 2023 | Mar 6, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −844 | $75.28 | $64K | 58.1Kdirect | Mar 2, 2023 | Mar 6, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −308 | $76.05 | $23K | 59.0Kdirect | Mar 2, 2023 | Mar 3, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −3,799 | $75.32 | $286K | 59.3Kdirect | Mar 2, 2023 | Mar 3, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −1,684 | $76.36 | $129K | 63.1Kdirect | Mar 1, 2023 | Mar 2, 2023 | Form 4 ↗ |
| Shah PriteshChief Growth Officer | Sale | −1,923 | $76.36 | $147K | 100.0Kdirect | Mar 1, 2023 | Mar 2, 2023 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −2,198 | $76.36 | $168K | 96.1Kdirect | Mar 1, 2023 | Mar 2, 2023 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −755 | $76.36 | $58K | 67.0Kdirect | Mar 1, 2023 | Mar 2, 2023 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,164 | $76.36 | $165K | 184.6Kdirect | Mar 1, 2023 | Mar 2, 2023 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −1,201 | $120.00 | $144K | 43.3Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −2,617 | $108.00 | $283K | 44.5Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −1,946 | $120.00 | $234K | 47.1Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −2,379 | $120.00 | $285K | 47.1Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −7,183 | $120.00 | $862K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −7,183 | $114.00 | $819K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −5,517 | $108.00 | $596K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −7,500 | $108.00 | $810K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −7,826 | $108.00 | $845K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −1,010 | $117.00 | $118K | 46.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −526 | $115.03 | $61K | 47.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −417 | $108.00 | $45K | 47.7Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −2,345 | $119.01 | $279K | 48.1Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −387 | $108.00 | $42K | 82.8Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −187.5K | $108.00 | $20.3M | 13.6Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −500 | $119.99 | $60K | 13.6Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −1,344 | $119.35 | $160K | 14.1Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −2,123 | $118.47 | $252K | 15.4Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −999 | $117.01 | $117K | 17.6Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −1,395 | $116.06 | $162K | 18.5Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −3,702 | $115.21 | $427K | 19.9Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −4,568 | $114.35 | $522K | 23.6Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −2,000 | $112.86 | $226K | 28.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −8,369 | $111.23 | $931K | 30.2Kdirect | Jan 5, 2023 | Jan 9, 2023 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −6,754 | $76.01 | $513K | 43.6Kdirect | Oct 13, 2022 | Oct 17, 2022 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −6,754 | $84.37 | $570K | 50.4Kdirect | Oct 6, 2022 | Oct 7, 2022 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −6,754 | $77.35 | $522K | 57.1Kdirect | Sep 29, 2022 | Sep 30, 2022 | Form 4 ↗ |
| Leonard Frank XPresident, CNS Cancers US | Sale | −6,754 | $77.00 | $520K | 63.9Kdirect | Sep 22, 2022 | Sep 26, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −5,517 | $90.00 | $497K | 70.6Kdirect | Sep 15, 2022 | Sep 19, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −6,754 | $87.31 | $590K | 76.2Kdirect | Sep 15, 2022 | Sep 19, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,863 | $88.00 | $164K | 84.2Kdirect | Sep 9, 2022 | Sep 12, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale Amended | −6,754 | $81.48 | $550K | 77.4Kdirect | Sep 8, 2022 | Sep 13, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,384 | $78.57 | $109K | 86.0Kdirect | Sep 6, 2022 | Sep 7, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −718 | $79.04 | $57K | 55.5Kdirect | Sep 2, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −885 | $79.04 | $70K | 72.4Kdirect | Sep 2, 2022 | Sep 6, 2022 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −296 | $79.04 | $23K | 165.0Kdirect | Sep 2, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −269 | $79.04 | $21K | 83.2Kdirect | Sep 2, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −584 | $79.04 | $46K | 87.4Kdirect | Sep 2, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −48 | $78.96 | $4K | 88.0Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −438 | $78.14 | $34K | 88.0Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −360 | $77.06 | $28K | 88.5Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −240 | $75.88 | $18K | 88.8Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,088 | $78.68 | $86K | 89.1Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −2,720 | $77.92 | $212K | 90.2Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,750 | $76.96 | $135K | 92.9Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,200 | $75.93 | $91K | 94.6Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −452 | $78.66 | $36K | 95.8Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −2,955 | $78.09 | $231K | 96.3Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,914 | $77.00 | $147K | 99.2Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −1,047 | $75.94 | $80K | 101.1Kdirect | Sep 1, 2022 | Sep 6, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −5,396 | $74.00 | $399K | 28.7Kdirect | Aug 3, 2022 | Aug 4, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −563 | $71.09 | $40K | 34.1Kdirect | Aug 3, 2022 | Aug 4, 2022 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −837 | $69.66 | $58K | 551.2Kdirect | Aug 2, 2022 | Aug 3, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −437 | $69.66 | $30K | 34.6Kdirect | Aug 2, 2022 | Aug 3, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −414 | $69.66 | $29K | 102.2Kdirect | Aug 2, 2022 | Aug 3, 2022 | Form 4 ↗ |
| HILLEMAN JERYL LDirector | Sale | −407 | $69.61 | $28K | 2,537direct | Jun 10, 2022 | Jun 16, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −2,135 | $61.25 | $131K | 34.8Kdirect | May 11, 2022 | May 12, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −2,070 | $65.16 | $135K | 37.0Kdirect | May 10, 2022 | May 12, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −3,669 | $71.19 | $261K | 83.2Kdirect | Mar 9, 2022 | Mar 11, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,481 | $70.10 | $174K | 81.9Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −744 | $70.10 | $52K | 102.3Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −1,037 | $70.10 | $73K | 56.0Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,923 | $70.10 | $205K | 165.1Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −759 | $70.10 | $53K | 60.8Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −2,339 | $70.10 | $164K | 62.5Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −2,385 | $70.10 | $167K | 552.0Kdirect | Mar 8, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −5,294 | $69.55 | $368K | 84.4Kdirect | Mar 7, 2022 | Mar 9, 2022 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −1,973 | $70.41 | $139K | 64.8Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −556 | $70.41 | $39K | 61.6Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −1,914 | $70.41 | $135K | 89.7Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,632 | $73.34 | $193K | 91.6Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,510 | $70.41 | $106K | 43.3Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −1,026 | $70.41 | $72K | 57.0Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,569 | $70.41 | $181K | 168.0Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −555 | $70.41 | $39K | 103.0Kdirect | Mar 4, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −1,094 | $74.50 | $82K | 66.8Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −1,149 | $74.50 | $86K | 62.2Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −997 | $74.50 | $74K | 94.2Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −803 | $74.50 | $60K | 44.8Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −341 | $74.50 | $25K | 58.1Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −1,301 | $74.50 | $97K | 170.6Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −930 | $74.50 | $69K | 103.6Kdirect | Mar 3, 2022 | Mar 7, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −399 | $76.03 | $30K | 50.9Kdirect | Jan 3, 2022 | Jan 5, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −919 | $76.09 | $70K | 49.9Kdirect | Jan 3, 2022 | Jan 5, 2022 | Form 4 ↗ |
| Burke William PatrickChief Human Resources Officer | Sale | −2,633 | $75.96 | $200K | 41.0Kdirect | Jan 3, 2022 | Jan 5, 2022 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Purchase | +104 | $96.50 | $10K | 13.3Kdirect | Nov 26, 2021 | Nov 29, 2021 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Purchase | +1,000 | $103.37 | $103K | 13.2Kdirect | Nov 26, 2021 | Nov 29, 2021 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Purchase | +3,870 | $102.36 | $396K | 12.2Kdirect | Nov 26, 2021 | Nov 29, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −209 | $107.28 | $22K | 41.8Kdirect | Nov 2, 2021 | Nov 3, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −30 | $140.18 | $4K | 73.5Kdirect | Sep 3, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −150 | $139.24 | $21K | 73.5Kdirect | Sep 3, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −321 | $138.27 | $44K | 73.7Kdirect | Sep 3, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −540 | $138.23 | $75K | 87.2Kdirect | Sep 2, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −828 | $138.23 | $114K | 42.0Kdirect | Sep 2, 2021 | Sep 7, 2021 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −181 | $138.23 | $25K | 149.9Kdirect | Sep 2, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −156 | $138.23 | $22K | 74.0Kdirect | Sep 2, 2021 | Sep 7, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −2,606 | $140.90 | $367K | 46.0Kdirect | Aug 12, 2021 | Aug 16, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −7,298 | $140.90 | $1.0M | 46.0Kdirect | Aug 12, 2021 | Aug 16, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −2,767 | $140.90 | $390K | 46.0Kdirect | Aug 12, 2021 | Aug 16, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −8,026 | $140.90 | $1.1M | 46.0Kdirect | Aug 12, 2021 | Aug 16, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −5,927 | $141.06 | $836K | 46.0Kdirect | Aug 12, 2021 | Aug 16, 2021 | Form 4 ↗ |
| Madden Martin J.Director | Sale | −34 | $153.13 | $5K | 384indirect | Aug 5, 2021 | Aug 6, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −1,000 | $152.50 | $153K | 72.9Kdirect | Aug 5, 2021 | Aug 6, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,063 | $148.71 | $307K | 74.2Kdirect | Aug 4, 2021 | Aug 6, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −328 | $149.43 | $49K | 89.2Kdirect | Aug 3, 2021 | Aug 4, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −1,654 | $149.43 | $247K | 76.2Kdirect | Aug 3, 2021 | Aug 4, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −464 | $150.11 | $70K | 28.1Kdirect | Aug 3, 2021 | Aug 4, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −713 | $149.38 | $107K | 89.5Kdirect | Aug 2, 2021 | Aug 4, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −995 | $149.38 | $149K | 554.4Kdirect | Aug 2, 2021 | Aug 4, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −536 | $149.38 | $80K | 28.6Kdirect | Aug 2, 2021 | Aug 3, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −651 | $158.96 | $103K | 29.1Kdirect | Jul 30, 2021 | Aug 3, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −1,000 | $183.54 | $184K | 72.9Kdirect | Jul 6, 2021 | Jul 8, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −23.5K | $215.00 | $5.1M | 77.7Kdirect | Jun 10, 2021 | Jun 11, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −1,000 | $204.55 | $205K | 72.0Kdirect | Jun 7, 2021 | Jun 8, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,833 | $200.00 | $367K | 29.1Kdirect | May 27, 2021 | May 28, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,943 | $180.48 | $351K | 29.1Kdirect | May 12, 2021 | May 14, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −2,262 | $180.12 | $407K | 31.0Kdirect | May 11, 2021 | May 12, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,833 | $189.65 | $348K | 33.3Kdirect | May 10, 2021 | May 12, 2021 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −1,804 | $189.65 | $342K | 31.7Kdirect | May 10, 2021 | May 12, 2021 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −3,846 | $189.65 | $729K | 33.5Kdirect | May 10, 2021 | May 12, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −1,290 | $199.67 | $258K | 101.3Kdirect | May 5, 2021 | May 6, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −1,000 | $199.67 | $200K | 72.0Kdirect | May 5, 2021 | May 6, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −1,043 | $200.86 | $209K | 102.6Kdirect | May 4, 2021 | May 5, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −600 | $216.69 | $130K | 555.4Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −500 | $214.67 | $107K | 556.0Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,500 | $213.35 | $320K | 556.5Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −600 | $211.28 | $127K | 558.0Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −521 | $210.18 | $110K | 558.6Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −2,200 | $209.34 | $461K | 559.1Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −4,500 | $207.80 | $935K | 561.3Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,284 | $206.35 | $265K | 565.8Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,600 | $205.43 | $329K | 567.1Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,972 | $204.28 | $403K | 568.7Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −2,555 | $203.25 | $519K | 570.7Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −4,388 | $202.16 | $887K | 573.2Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −4,125 | $201.55 | $831K | 577.6Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −4,338 | $199.71 | $866K | 581.7Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −10.6K | $198.98 | $2.1M | 586.1Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −13.6K | $197.83 | $2.7M | 596.6Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −24.3K | $197.00 | $4.8M | 610.3Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −8,814 | $196.07 | $1.7M | 634.6Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,600 | $194.94 | $312K | 643.4Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −2,090 | $193.57 | $405K | 645.0Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,900 | $192.52 | $366K | 647.1Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −1,400 | $191.26 | $268K | 649.0Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| Danziger AsafChief Executive Officer · Director | Sale | −98.0K | $196.34 | $19.2M | 8,184direct | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −2,500 | $200.00 | $500K | 72.0Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| LEUNG GABRIELDirector | Sale | −3,500 | $198.01 | $693K | 74.5Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −3,474 | $200.00 | $695K | 33.3Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −651 | $200.00 | $130K | 33.3Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,833 | $200.00 | $367K | 33.3Kdirect | Apr 13, 2021 | Apr 15, 2021 | Form 4 ↗ |
| DOYLE WILLIAM FExecutive Chairman · Director | Sale | −7,928 | $134.12 | $1.1M | 650.4Kdirect | Apr 1, 2021 | Apr 2, 2021 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale Amended | −2,835 | $140.00 | $397K | 33.5Kdirect | Mar 23, 2021 | Apr 9, 2021 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −3,892 | $140.00 | $545K | 36.3Kdirect | Mar 23, 2021 | Mar 25, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −3,524 | $131.09 | $462K | 101.3Kdirect | Mar 9, 2021 | Mar 10, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,627 | $130.81 | $344K | 104.8Kdirect | Mar 8, 2021 | Mar 10, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −765 | $130.81 | $100K | 35.9Kdirect | Mar 8, 2021 | Mar 10, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −2,404 | $130.81 | $314K | 67.7Kdirect | Mar 8, 2021 | Mar 10, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −765 | $130.81 | $100K | 90.0Kdirect | Mar 8, 2021 | Mar 10, 2021 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −3,004 | $130.81 | $393K | 153.7Kdirect | Mar 8, 2021 | Mar 10, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −4,550 | $131.53 | $598K | 107.4Kdirect | Mar 5, 2021 | Mar 9, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −2,918 | $131.53 | $384K | 33.3Kdirect | Mar 5, 2021 | Mar 9, 2021 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −3,854 | $137.55 | $530K | 156.7Kdirect | Mar 4, 2021 | Mar 8, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −3,084 | $137.55 | $424K | 70.1Kdirect | Mar 4, 2021 | Mar 8, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −567 | $137.55 | $78K | 90.8Kdirect | Mar 4, 2021 | Mar 8, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −567 | $137.55 | $78K | 37.6Kdirect | Mar 4, 2021 | Mar 8, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −1,888 | $137.55 | $260K | 36.2Kdirect | Mar 4, 2021 | Mar 5, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,658 | $137.55 | $366K | 98.0Kdirect | Mar 4, 2021 | Mar 5, 2021 | Form 4 ↗ |
| Benaim ElyChief Medical Officer | Sale | −3,475 | $150.78 | $524K | 38.1Kdirect | Mar 3, 2021 | Mar 5, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −2,174 | $150.78 | $328K | 100.6Kdirect | Mar 3, 2021 | Mar 5, 2021 | Form 4 ↗ |
| Leonard Frank XChief Development Officer | Sale | −430 | $152.05 | $65K | 82.7Kdirect | Mar 2, 2021 | Mar 4, 2021 | Form 4 ↗ |
| Cordova AshleyChief Financial Officer | Sale | −428 | $152.05 | $65K | 27.2Kdirect | Mar 2, 2021 | Mar 4, 2021 | Form 4 ↗ |
| GROENHUYSEN WILHELMUS CMChief Operating Officer | Sale | −2,392 | $152.05 | $364K | 148.0Kdirect | Mar 2, 2021 | Mar 4, 2021 | Form 4 ↗ |
| Shah PriteshChief Commercial Officer | Sale | −912 | $152.05 | $139K | 91.9Kdirect | Mar 2, 2021 | Mar 4, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −2,355 | $152.05 | $358K | 62.9Kdirect | Mar 2, 2021 | Mar 4, 2021 | Form 4 ↗ |
| Weinberg UriChief Science Officer | Sale | −6,500 | $175.50 | $1.1M | 27.6Kdirect | Feb 22, 2021 | Feb 24, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −1,200 | $179.30 | $215K | 59.7Kdirect | Jan 15, 2021 | Jan 19, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −900 | $178.50 | $161K | 60.9Kdirect | Jan 15, 2021 | Jan 19, 2021 | Form 4 ↗ |
| Longsworth Todd ChristopherGeneral Counsel | Sale | −2,841 | $177.33 | $504K | 61.8Kdirect | Jan 15, 2021 | Jan 19, 2021 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →